R3VIVE.ME CJC-1295 w/o DAC & Ipamorelin 20mg is a research-grade peptide blend developed for laboratory studies involving growth hormone pathway observation, recovery-focused signalling research, and peptide-response modelling.

This formulation contains:

• Modified GRF 1-29 (CJC-1295 without DAC) – 10mg
• Ipamorelin – 10mg

The combination is commonly referenced in controlled research environments for pulsatile growth hormone signalling studies, recovery-response observation, and advanced peptide interaction modelling.

CJC-1295 without DAC is frequently examined for short-acting growth hormone releasing hormone (GHRH) pathway activity, while Ipamorelin is studied for selective ghrelin receptor interaction and growth hormone secretagogue research.

Together, the blend is commonly utilised in peptide studies involving recovery optimisation, tissue-support modelling, and hormonal signalling observation.

Key Features(R3VIVE.ME CJC-1295)

• Dual-peptide growth hormone research blend
• Contains CJC-1295 w/o DAC and Ipamorelin
• Examined for GH signalling and recovery studies
• Suitable for peptide-response and regenerative modelling
• Research-grade peptide formulation

How to Use (Research Reference Only)

Research literature evaluates peptide blends using structured laboratory protocols within controlled environments.

This information is provided strictly for scientific context and is not guidance for human use.

Stacking (Research Context)

In laboratory environments, this peptide blend may be examined alongside:

• Recovery peptide formulations
• NAD+ metabolic pathway studies
• Regenerative and tissue-support research compounds

Stacking depends entirely on research objectives.

Research Disclaimer (R3VIVE.ME CJC-1295 w/o DAC & Ipamorelin 20mg )

For laboratory and scientific research use only.
Not intended for human consumption, medical treatment, or veterinary application.

What is CJC-1295 & Ipamorelin?

CJC-1295 without DAC and Ipamorelin are research peptides studied in laboratory environments for growth hormone signalling, recovery optimisation, regenerative pathways, and peptide-response modelling.